Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg has maintained a Neutral rating on Pacific Biosciences (NASDAQ:PACB) and lowered the price target from $13 to $9.
October 16, 2023 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on Pacific Biosciences and lowered the price target from $13 to $9.
The lowering of the price target by Piper Sandler from $13 to $9 indicates a bearish outlook for Pacific Biosciences. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100